#USA #Boston #obesity #Mwyngil Therapeutics #GPR75

Mwyngil Therapeutics Unveils Promising Data for Obesity Treatment

Mwyngil Therapeutics, a cutting-edge biotech firm devoted to innovative therapies for cardiometabolic conditions, recently announced groundbreaking in vivo proof-of-concept findings related to its GPR75 inverse agonist program. This development signifies a potential game changer in the treatment of obesity and associated cardiometabolic issues.

In a recent study involving a mouse model with diet-induced obesity (DIO), the company’s lead oral compounds produced impressive results, demonstrating up to a 25% reduction in body weight. This weight loss was notably accompanied by a preferential decrease in fat rather than muscle mass, indicating a significant advance in obesity treatment focused on enhancing overall health rather than just weight metrics. The findings revealed a remarkable 33–50% reduction in fat rate and a 1.5-fold decrease in epididymal white adipose tissue (eWAT), contributing to a more favorable body composition.

Beyond mere weight reduction, the study also spotlighted extensive metabolic improvements. Notable results included enhanced glycemic control evidenced by lowering fasting blood glucose and HbA1c levels, a decrease in systemic inflammatory markers like CRP and IL-18, and a reduction in liver weight alongside improved hepatic and lipid biomarkers, including ALT/AST and total cholesterol levels.

Luba Greenwood, the CEO of Mwyngil Therapeutics, praised these findings, stating, “These results suggest that GPR75 inverse agonism may offer a differentiated obesity profile focused on quality weight loss rather than weight reduction alone.” The data affirms not only Mwyngil's meticulous research but also the integral role of GPR75 in systemic metabolic regulation.

The development of these compounds is rooted in robust human genetic validation of GPR75, as a substantial study involving approximately 640,000 individuals discovered loss-of-function variants in GPR75 associated with reduced body mass index (BMI) and a lowered risk of obesity. Concurrently, GPR75 knockout mice displayed markedly diminished vulnerability to weight gain induced by diets. Mwyngil’s compounds were designed as selective oral allosteric inverse agonists intended to fine-tune central metabolic pathways. These lead molecules demonstrated functional potency in the lower double-digit nanomolar range in a specific cell-based β-arrestin assay, suggesting favorable selectivity and characteristics for further development.

In contrast to methods that primarily target appetite suppression, Mwyngil’s approach seeks to influence central energy balance via modulation of GPR75 signaling, directly linked to obesity and metabolic disorders. The firm is committed to advancing this promising program, with plans to move toward a development candidate after the completion of ongoing translational and preclinical activities.

About Mwyngil Therapeutics

Mwyngil Therapeutics is focused on pioneering oral small-molecule therapies targeting genetically validated pathways in obesity and cardiometabolic diseases. With its GPR75 program, the company aims for clinically relevant weight loss while safeguarding lean mass and promoting enhanced metabolic health outcomes. Other initiatives in its pipeline include brain-penetrant molecules targeting additional metabolic pathways such as PTP-1B and NLRP3.

For more updates, visit their website at Mwyngil.com.